Survey respondents’ knowledge and awareness of various medical conditions.

Survey respondents’ knowledge and awareness of various medical conditions.</p

Dataset and summary data for women who had heard of cytomegalovirus.

(XLSX)</p

Knowledge of CMV modes of transmission among survey respondents that previously heard of CMV.

Knowledge of CMV modes of transmission among survey respondents that previously heard of CMV.</p

Knowledge of symptoms of congenital CMV among survey respondents that previously heard of CMV.

Knowledge of symptoms of congenital CMV among survey respondents that previously heard of CMV.</p

Sociodemographic characteristics of survey respondents and their association with knowledge of CMV.

Sociodemographic characteristics of survey respondents and their association with knowledge of CMV.</p

Knowledge of preventative measures against CMV among survey respondents that previously heard of CMV.

Knowledge of preventative measures against CMV among survey respondents that previously heard of CMV.</p

Dataset and summary data for all study participants.

(XLSX)</p

Cytomegalovirus awareness and knowledge questionnaire in Arabic and English languages.

(PDF)</p

Hearing loss in mCMV infected C57BL/6 mice after disruption of NK cell recognition signals.

<p>The effect of Ly49H receptor blockade on hearing loss was evaluated by examining distortion product otoacoustic emission (DPOAE) (A) and auditory brainstem response (ABR) (B) thresholds in post-natal day 28 (4 wks) and post-natal day 42 (6 wks) after intraperitoneal injection of IgG isotype control antibody or Ly49H blocking antibody and/or 200 pfu mCMV-GFP delivered by intracerebral injection on post-natal day 3. Statistically significant threshold differences were seen between the infected mice treated with the IgG isotype control antibody (N = 12 mice) and infected mice treated with the Ly49H blocking antibody 4 weeks post-injection (N = 8 mice) for DPOAE (<i>P</i> < 0.0001) and ABR (<i>P</i> = 0.0001) over the measured tone frequencies. Infected C57BL/6 mice treated with anti-Ly49H antibody and mCMV-GFP showed significant progressive hearing loss at 6 weeks after inoculation compared to thresholds 4 weeks after inoculation (<i>P</i> = 0.001 for DPOAE, <i>P</i> < 0.0001 for ABR). The effect of the mCMV-encoded m157 immunoevasin ligand on hearing loss was tested by comparing DPOAE (C) and ABR (D) in C57BL/6 mice after infection with either a virus deleted for the m157 gene (mCMV Δm157) or its parental wild type virus (mCMV WT1). Statistically significant threshold differences (<i>P</i> < 0.001) were seen between the mCMV WT1 and mCMV Δm157 treated C57BL/6 groups (<i>P</i> < 0.0001 for both DPOAE and ABR). Statistical differences between groups were determined using the Kruskal-Wallis test. ABR and DPOAE thresholds are presented as dB of sound pressure level (dB SPL) as a function of tone frequency in (kHz). Error bars represent standard error of the mean.</p

Ly49H blockade induces co-localization of mCMV-GFP infected cells and NK cells within the temporal bone.

<p>Green fluorescent protein expressed in mCMV-GFP infected cells and red fluorescent protein expressed in NK cells were visualized in cochlear cryosections from NK1.1-tdTomato knock-in mouse temporal bones harvested 3 days post-injection using anti-GFP (green) and anti-RFP antibodies (red). Representative images of 3–4 cochleae examined per group are shown for NK1.1-tdTomato knock-in mice injected with anti-Ly49H antibody only (A), mCMV-GFP only (B), or both (C). Panel D depicts a higher magnification of the auditory nerve region indicated by * in panel B. Panel E depicts a higher magnification of the spiral ganglion region indicated by * in panel C. Scale bars indicate 500 μm in panels A, B, and C and 100 μm in panels D and E. st = scala tympani.</p